Could there be a long-awaited breakthrough in first-line therapy for triple-negative breast cancer?
Update: 2025-10-28
Description
New research presented at ESMO 2025 confirms that datopotamab deruxtecan significantly improves progression-free and overall survival compared with chemotherapy in advanced triple-negative breast cancer, supporting its role as a first-line standard of care. Updated SELECT trial analyses demonstrate that semaglutide reduces major cardiovascular events by 20% independent of weight loss, suggesting cardioprotective mechanisms beyond adiposity reduction. Long-term data show that HPV vaccination has led to dramatic declines in vaccine-type infections and strong herd protection, although global coverage remains suboptimal.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
